BCAX · Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

116 Huntington Avenue, Boston, MA, 02116, United States
Biotechnology
Healthcare

Market Cap

560.3M

52 Wk Range

$7.87 - $30.99

Previous Close

$9.12

Open

$8.83

Volume

814,508

Day Range

$8.43 - $9.14

Enterprise Value

164M

Cash

442.3M

Avg Qtr Burn

-56.13M

Insider Ownership

10.04%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026